Current status and progress of recurrence of retinopathy in prematurity after intravitreal injection with anti-vascular endothelial growth factor drugs / 中华眼底病杂志

ABSTRACT

Intravitreal injection of anti-VEGF drugs for the treatment of retinopathy of prematurity (ROP) is a hot topic of research,and it can be used to treat the ROP (Ⅰ zone).The current anti-VEGF drugs include bevacizumab,ranibizumab,aflibercept and conbercept,etc.However,in recent years,several studies have confirmed that anti-VEGF drugs have an increased recurrence rate and a longer recurrence time than conventional laser photocoagulation therapy.The follow-up period should be extended and repeated injections may be required.Due to the lack of large-scale prospective clinical studies,the recurrence rate,time window of recurrence,risk factors and treatment methods of various anti-VEGF drugs for ROP are still unclear.Anti-VEGF drugs in the treatment of ROP needs to accumulate more evidence-based medical evidence.